share_log

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More

生物技術行業未來一週（5月22日至28日）：Verrica、百時美施貴寶FDA決定、美敦力業績、會議演講等
Benzinga Real-time News ·  2022/05/23 04:00
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
生物科技股在截至5月22日的一週內上漲，無視大盤的回落。該行業的防禦性和特定於股票的走勢為其提供了支持。
The spread of the monkey pox virus in the U.S. and Europe sparked a rally in companies working on vaccine candidates against viruses. GeoVax Labs, Inc. (NASDAQ:GOVX) was the biggest beneficiary, with its stock more than doubling in the week.
猴痘病毒在美國和歐洲的傳播引發了研究疫苗候選的公司的反彈。GeoVax實驗室，Inc.納斯達克(GOVX：GOVX)是最大的受益者，其股價在本週上漲了一倍多。
NanoViricides, Inc. (NYSE:NNVC) also advanced strongly following positive clinical updates provided by the company.
納米病毒公司(紐約證券交易所市場代碼：NNVC)也在該公司提供積極的臨床更新後強勁上漲。
On the regulatory front, Sanofi (NASDAQ:SNY)-Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received the Food and Drug Administration...
在監管方面，賽諾菲(納斯達克：SNY...
登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論